Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Apr 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2017.
- 03 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2017.